Skip to main content

Table 1 Baseline characteristics of enrolled patients

From: A model with combined viral and metabolic factors effectively predicts HBeAg status under long term entecavir therapy: a prospective cohort study

Characteristics

HBeAg positive

(n = 229)

Age,yr

30.7 ± 7.6

Male,(%)

177(77 %)

BMI (kg/m2)

22.3 ± 2.4

Cirrhosis

23(10 %)

Median treatment duration

212(84–337)

Median HBV DNA(log10copies/ml)

8.1 ± 1.3

Serum ALT (IU/L)

134.2 ± 93.5

Serum AST (IU/L)

81.2 ± 54.0

Serum ALP (IU/L)

103.1 ± 32.6

Total bilirubin (mg/dL)

0.9 ± 0.3

Serum albumin (g/L)

45.2 ± 3.5

Platelet count (10^9/L)

153.1 ± 80.0

Serum creatinine (mg/dl)

0.9 ± 0.2

WBC (10^9/L)

5.4 ± 1.4